Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 3/20 | 0.75 |
| ▸ | RCOR1 | Q9UKL0 | 2/20 | 0.75 |
| ▸ | PSMB5 | P28074 | 11/20 | 0.45 |
| ▸ | PSMB2 | P49721 | 7/20 | 0.45 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
| ▸ | LCK | P06239 | 1/20 | 0.44 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.43 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.43 |
| ▸ | NPY1R | P25929 | 1/20 | 0.42 |
| ▸ | NPY2R | P49146 | 1/20 | 0.42 |
| ▸ | NPY4R | P50391 | 1/20 | 0.42 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21504399 | 0.94 | KDM1A (0.78) | KDM1ARCOR1PSMB5PSMB2SLC40A1 | |
| SCHEMBL21474143 | 0.94 | KDM1A (0.78) | KDM1ARCOR1PSMB5PSMB2SLC40A1 | |
| SCHEMBL21474059 | 0.94 | KDM1A (0.81) | KDM1ARCOR1PSMB5PSMB2SLC40A1 | |
| SCHEMBL21474103 | 0.94 | KDM1A (0.81) | KDM1ARCOR1PSMB5PSMB2SLC40A1 | |
| SCHEMBL21474101 | 0.94 | KDM1A (0.81) | KDM1ARCOR1PSMB5PSMB2SLC40A1 | |
| SCHEMBL21474100 | 0.94 | KDM1A (0.81) | KDM1ARCOR1PSMB5PSMB2SLC40A1 | |
| SCHEMBL21476980 | 0.93 | KDM1A (0.80) | KDM1ARCOR1PSMB5PSMB2SLC40A1 | |
| SCHEMBL25645022 | 0.93 | KDM1A (0.80) | KDM1ARCOR1PSMB5PSMB2SLC40A1 | |
| SCHEMBL21474145 | 0.93 | KDM1A (0.80) | KDM1ARCOR1PSMB5PSMB2SLC40A1 | |
| SCHEMBL21474061 | 0.93 | KDM1A (0.85) | KDM1ARCOR1PSMB5PSMB2SLC40A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3556769-A1 | POLYMYXIN DERIVATIVE, PREPARATION METHOD AND APPLICATION THEREOF | Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences (CN) | 2019-10-23 | — | — | EP | disclosed |
| US-20190315806-A1 | POLYMYXIN DERIVATIVE, PREPARATION METHOD AND APPLICATION THEREOF | INSTITUTE OF MEDICINAL BIOTECHNOLOGY, CAMS (CN) | 2019-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190315806-A1 | POLYMYXIN DERIVATIVE, PREPARATION METHOD AND APPLICATION THEREOF | NPEPPS, MYD88, MRPL21 | KDM1A 2143/4885RCOR1 1398/4885PSMB5 292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.